Nivolumab and Oral Cyclophosphamide for Relapsed/Refractory Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndrome (MDS)

Trial Profile

Nivolumab and Oral Cyclophosphamide for Relapsed/Refractory Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndrome (MDS)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Cyclophosphamide (Primary) ; Nivolumab (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 05 Apr 2018 Planned End Date changed from 1 Jan 2022 to 1 Feb 2022.
    • 05 Apr 2018 Planned primary completion date changed from 1 Jan 2020 to 1 Feb 2020.
    • 05 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top